Precision Medicine

A landmark partnership is digitizing millions of tissue samples across Europe, centralizing expertise and paving the way for AI-driven precision medicine.

With a new FDA nod for its rare disease drug Joenja, Pharming offers hope to young children, signaling a strategic shift in how we treat complex genetic disorders.

The oncology firm's revenue dips and losses widen, but a strategic shift to hospitals and key regulatory wins may pave the way for long-term growth.

As Aktis Oncology presents at key investor conferences, it showcases a precision miniprotein platform and a major Eli Lilly deal in a booming market.

A veteran team with a pharma exit under its belt just raised $10.8M to aim AI at a notoriously tough drug target. Here’s why investors are buying the signal.

Newly restructured Niki BioSolutions faces Wall Street at a key conference, pitching its brain health innovations while battling steep losses and investor doubt.

As BioVie seeks FDA approval for a pivotal Phase 3 trial, its novel anti-inflammatory drug could usher in a new era for Parkinson's patients.

A breakthrough in proteomics allows Nautilus Biotechnology to map individual disease-linked proteins, promising to revolutionize diagnostics and drug discovery.

Kala Bio's new deal with Virotek isn't just about eye care. It's a capital-efficient pivot that tests its new identity and bets on a commercial present.

The Israeli biotech firm gained crucial FDA feedback for its personalized therapy, NewRal. But in a field laden with failure, is this a true breakthrough?

Northway Biotech's new Vilnius hub isn't just a factory; it's a strategic move to dominate Europe's advanced therapy market. A deep dive into the investment.

Life Line Screening's p-tau217 test democratizes Alzheimer's risk assessment, raising critical questions about non-diagnostic data and patient well-being.

By appointing two legendary specialists, XGEN isn't just shuffling its board. It's aiming to legitimize whole genome sequencing for all IVF patients.

As Alamar Biosciences prepares for a key fireside chat at Morgan Stanley, all eyes are on its NULISA™ technology and its rapid commercial growth.

Beyond the pink ribbons, the CIBC Run for the Cure is a funding powerhouse. We unpack the 30-year alliance that's fueling AI-driven diagnostics and policy battles.

A $10M federal contract aims to slash the 7-year wait for rare disease diagnoses. Discover how Probably Genetic's AI and direct-to-patient data are leading the charge.

A strategic merger combines Chemomab's promising drug, nebokitug, with Scipher's AI platform, aiming to de-risk development and transform RA treatment.

XYRA's new trial uses data from wearables to personalize doses of Budiodarone, a safer alternative to today's standard AF drugs. Is this the future?

A landmark UCSF study has mapped the molecular machinery of autism, revealing convergent pathways. This isn't just a breakthrough for ASD; it's a new model for drug discovery.

As precision medicine generates a deluge of data, Iylon Oncology's appointment of Dr. Mary Lopresti shows the real value is not in the algorithm, but in human expertise.